[New Therapeutic Options for the Individualised Titration of Levodopa].
| Autor: | Jost WH; Parkinson-Klinik Ortenau, Wolfach., Ebersbach G; Neurologisches Fachkrankenhaus für Bewegungsstörungen / Parkinson, Beelitz-Heilstätten., Kassubek J; Neurologische Universitätsklinik Ulm, RKU., Klebe S; Klinik für Neurologie, Universitätsklinik Essen., Tönges L; Neurologische Klinik der Ruhr-Universität Bochum, St. Josef-Hospital, Bochum. |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Fortschritte der Neurologie-Psychiatrie [Fortschr Neurol Psychiatr] 2021 Jan; Vol. 89 (1-02), pp. 23-28. Date of Electronic Publication: 2020 May 27. |
| DOI: | 10.1055/a-1158-9281 |
| Abstrakt: | Levodopa is the most effective medication in the treatment of Parkinson's disease. In the course of the disease the storage facility of dopaminergic neurones deteriorates, so that the duration of the half-life period likewise converges. This results in fluctuations in performance, and also in dyskinesias as a further consequence of the narrowing therapeutic window. Therapeutically, this in turn leads to further fractioning of the levodopa dosage and a reduction of single-dose levels. There is, however, only limited scope for doing this with the conventional levodopa formulations. For this reason, the introduction of water-soluble microtablets à 5 / 1.25 mg levodopa / carbidopa can be regarded as a beneficial extension permitting for fine titration of the dopaminergic stimulation. Here we present this new therapeutic principle, the available data and concepts for clinical use. Competing Interests: Der Expertenworkshop fand am 12. Dezember 2019 in Frankfurt mit freundlicher Unterstützung der Desitin Arzneimittel GmbH statt. Die Teilnehmer des Workshops erhielten finanzielle Unterstützung durch die Desitin Arzneimittel GmbH, Hamburg. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|